Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 | Synapse
October 17, 2025Open Access
Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Key Points
The study assesses demographics of women receiving camizestrant combined with CDK4/6 inhibitors.
Patient profiles include those treated with abemaciclib, palbociclib, or ribociclib for advanced breast cancer.
Baseline characteristics outline the context of therapy for ER+ and HER2− patients.
Findings can inform future treatment strategies in advanced breast cancer management.
Abstract
Baseline characteristics and patient demographics for camizestrant in combination with abemaciclib, palbociclib, or ribociclib.